Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy

Leukemia and Lymphoma

Volumn 49, Issue 5, 2008, Pages 939-947

  Cil, Timucin ^a   Altintas, Abdullah ^a   Pasa, Semir ^a   Bayan, Kadim ^a   Ozekinci, Tuncer ^a   Isikdogan, Abdurrahman ^a  

^a DICLE UNIVERSITY   (Turkey)

Author keywords

Hepatic flare up; Hepatitis B virus; Lamivudine

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTHRACYCLINE; ASPARTATE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; HEPATITIS B SURFACE ANTIGEN; IBRITUMOMAB TIUXETAN; IRINOTECAN; LAMIVUDINE; RITUXIMAB; VINCRISTINE; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B CELL LYMPHOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLON CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HEPATITIS; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALE; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; TREATMENT RESPONSE; VIRUS REACTIVATION;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NEOPLASMS; PREVALENCE; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 46749098315     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190801975568     Document Type: Article

References (38)

1. Lee, W. M. (1997) Hepatitis B virus infection. N Engl J Med, 337, pp. 1733-1745.
2. Ustun, C., Koc, H., Karayalcin, S., Akyol, G., Gurman, G. and Ilhan, O. (1997) Hepatitis B virus infection in allogenic bone marrow transplantation. Bone Marrow Transplant, 20, pp. 289-296.
3. Mindikoglu, A. L., Regev, A. and Schiff, E. R. (2006) Hepatitis B virus reactivation after cytotoxic chemotherapy: The disease and its prevention. Clin Gastroenterol Hepatol, 4, p. 1076.
4. Lim, L. L., Wai, C. T., Lee, Y. M., Kong, H. L., Lim, R. and Koay, E. (2002) Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther, 16, pp. 1939-1944.
5. Yeo, W., Lam, K. C., Zee, B., Chan, P SK, Mo, F KF and Ho, W. M. (2004) Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol, 15, pp. 1661-1666.
6. Fattovich, G., Brollo, L., Alberti, A., Realdi, G., Pontisso, P. and Giustina, G. (1990) Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis. Liver, 10, pp. 141-146.
7. Tong, M. J., Sampliner, R. E., Govindarajan, S. and Co, R. L. (1987) Spontaneous reactivation of hepatitis B in Chinese patients with HBsAg-positive chronic active hepatitis. Hepatology, 7, pp. 713-718.
8. Davis, G. L. and Hoofnagle, J. H. (1985) Reactivation of chronic type B hepatitis presenting as acute viral hepatitis. Ann Intern Med, 102, pp. 762-765.
9. Davis, G. L., Hoofnagle, J. H. and Waggoner, J. G. (1984) Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology, 86, pp. 230-235.
10. Lok, A. S., Liang, R. H., Chiu, E. K., Wong, K. L., Chan, T. K. and Todd, D. (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology, 100, pp. 182-188.
11. Mehmet, D., Meliksah, E., Serif, Y., Gunay, S., Tuncer, O. and Zeynep, S. (2005) Prevalence of hepatitis B infection in the southeastern region of Turkey: Comparison of risk factors for HBV infection in rural and urban areas. Jpn J Infect Dis, 58, pp. 15-19.
12. Silvestri, F., Ermacora, A., Sperotto, A., Patriarca, F., Zaja, F. and Damiani, D. (2000) Lamivudine allows completion of chemotherapy in lymphoma patients with Hepatitis B reactivation. Br J Haematol, 108, pp. 394-396.
13. Persico, M., De Marino, F., Russo, G. D., Morante, A., Rotoli, B. and Torella, R. (2002) Efficiency of lamivudine to prevent hepatitis reactivation in hepatitis B virus infected patients treated for non-Hodgkin Lymphoma. Blood, 99, pp. 724-725.
14. Shibolet, O., Iian, Y., Gillis, S., Hubert, A., Shouval, D. and Safadi, R. (2002) Lamivudine therapy for prevention of immunosuppresive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood, 100, pp. 391-396.
15. Rossi, G., Pelizzari, A., Motta, M. and Puoti, M. (2001) Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol, 115, pp. 58-62.
16. Kohrt, H. E., Ouyang, D. L. and Keeffe, E. B. (2006) Systematic review: lamivudine prophylaxis for chemotherapy induced reactivation of chronic hepatitis B virus infection aliment. Pharmacol Ther, 24, p. 1003.
17. Yeo, W., Chan, P KS, Ho, W. M., Zee, B., Lam, K. C. and Lei, K IK (2004) Lamivudine for the Prevention of hepatitis B virus reactivation in hepatitis B antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol, 22, pp. 927-934.
18. Hoofnagle, J. H., Dusheiko, G. M., Schafer, D. F., Jones, E. A., Micetich, K. C. and Young, R. C. (1982) Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Int Med, 96, pp. 447-449.
19. Wands, J. R. (1975) subacute and chronic active hepatitis after withdrawal of chemotherapy. Lancet, 2, p. 979.
20. Nakamura, Y., Motokura, T. and Fujita, A. (1996) Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Cancer, 78, pp. 2210-2215.
21. Wasif Saif, M, Little, R. F., Hamilton, J. M., Allegra, C. J. and Wilson, W. H. (2001) Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: A case report and review of the literature. Ann Oncol, 12, pp. 123-129.
22. Kohrt, H. E., Ouyang, D. L. and Keeffe, E. B. (2007) Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis, 11, p. 965.
23. Hui, C. K., Cheung, W. W., Au, W. Y., Lie, A. K., Zhang, H. Y. and Yueng, Y. H. (2005) Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut, 54, pp. 1597-1603.
24. Idilman, R., Arat, M., Soydan, E., Toruner, M., Soykan, I. and Akbulut, H. (2004) Lamivudine prophylaxis for prevention of chemotherapy induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepatitis, 11, pp. 141-147.
25. Gutfreund, K. S., Williams, M., George, R., Bain, V. G., Ma, M. M. and Yoshida, E. M. (2000) Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol, 33, pp. 469-475.
26. Fischer, K. P., Gutfreund, K. S. and Tyrrell, D. L. (2001) Lamivudine resistance in hepatitis B: Mechanisms and clinical implications. Drug Resist Updat, 4, pp. 118-128.
27. Zoulim, F. (2001) Detection of hepatitis B virus resistance to antivirals. J Clin Virol, 21, pp. 243-253.
28. Lai, C. L., Chien, R. N., Leung, N. W., Chang, T. T., Guan, R. and Tai, D. I. (1998) A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med, 339, pp. 61-68.
29. Lam, K. C., Lai, C. L., Trepo, C. and Wu, P. C. (1981) Deleterious effect of prednisolone in HbsAg-positive chronic active hepatitis. N Engl J Med, 304, pp. 380-386.
30. Cheng, A. L. (1996) Steroid free chemotherapy decreases the risk of hepatitis flare ups in hepatitis B virus carriers with non-Hodgkin's lymphoma. Blood, 87, p. 1202.
31. Scullard, G. H., Smith, C. I. and Mengan, T. C. (1981) Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology, 81, pp. 987-991.
32. Sagnelh, E., Manzillo, G. and Maho, G. (1980) Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet, 2, pp. 395-397.
33. Takai, S., Tsurumi, H., Ando, K., Kasahara, S., Sawada, M. and Yamada, T. (2005) Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Hematol, 74, pp. 158-165.
34. Cheng, A. L., Hsiung, C. A., Su, I. J., Chen, P. J., Chang, M. C. and Tsao, C. J. (2003) Steroid free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology, 37, pp. 1320-1328.
35. Tsutsumi, Y., Kawamura, T., Saitoh, S., Yamada, M., Obara, S. and Miura, T. (2004) Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: Necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma, 45, pp. 627-629.
36. Shimizu, D., Nomura, K., Matsumoto, Y., Ueda, K., Yamaguchi, K. and Minami, M. (2004) Hepatitis B virus reactivation in a patient undergoing steroid-free chemotherapy. World J Gastroenterol, 10, pp. 2301-2302.
37. Sera, T., Hiasa, Y., Michitaka, K., Konishi, I., Matsuura, K. and Tokumoto, Y. (2006) Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med, 45, pp. 721-724.
38. Dervite, I., Hober, D. and Morel, P. (2001) Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med, 344, pp. 68-69.